The VEGFR2 gene is transcriptionally regulated during angiogenesis. The ability to monitor and quantify VEGFR2 expression in vivo may facilitate a better understanding of the role of VEGFR2 in different states. Here we describe a transgenic mouse, Vegfr2-luc, in which a luciferase reporter is under control of the murine VEGFR2 promoter. In adult mice, luciferase activity was highest in lung and uterus, intermediate in heart, skin and kidney, and lower in other tissues. Luciferase expression in these tissues correlated with endogenous VEGFR2 mRNA expression. In a cutaneous wound-healing model, Vegfr2-luc expression was induced in the wound tissue.
Introduction
Angiogenesis is the process of capillary sprouting from pre-existing blood vessels (1) . The angiogenesis process is characterized by vasodilation, increased plasma leakage, remodeling of the extracellular matrix, up-regulation of growth factor receptors, proliferation and differentiation of endothelial cells, and recruitment of pericytes and smooth muscle cells, followed by the deposition of new matrix proteins for tubule formation (2) . Endothelial cells are the source of new blood vessels and have a remarkable ability to divide and migrate. A finely tuned balance between factors that activate endothelial cell growth and those that inhibit it tightly controls new capillary growth.
Angiogenesis is regulated, in part, by several families of secreted growth factors that bind and activate their cognate receptors. One of the growth factors is vascular endothelial growth factor (VEGF), which exerts biological functions via two related receptor tyrosine kinases: vascular endothelial growth factor receptors-1 and -2 (VEGFR1 or FLT1, and VEGFR2 or Flk1/KDR). In addition, the VEGF signaling pathway may also involve neuropilin-1 and neuropilin-2 that are used as co-receptors by VEGFR2 and VEGFR1 (3) . The interaction of VEGF with its receptors is a critical part of angiogenesis. VEGFR2 mediates most of the mitogenic, survival and vascular permeability effects of VEGF (4, 5) . Angiogenesis is tightly controlled in the adult animal and occurs almost exclusively in the female reproductive system under normal conditions (6) .
However, angiogenesis can be activated in adult tissues during wound healing (7) and is important in certain pathological conditions such as tumorigenesis (8) , diabetic retinopathy (9), rheumatoid arthritis (10), psoriasis (11) and hypersensitive skin reactions (12, 13) .
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Angiogenesis is an important part of wound healing (1) , which involves the induction of proinflammatory cytokines and various growth factors necessary for this process (14) . Growth factors specific to endothelial cells, such as VEGF, are critically involved in cutaneous angiogenesis (15) .
During normal wound healing (16) and some pathological conditions such as delayed hypersensitivity skin reactions, VEGF expression correlates both temporally and spatially with the proliferation of new blood vessels (12) . In addition, the receptors for VEGF, VEGFR1 and VEGFR2, are induced in dermal capillaries during wound healing (17, 18) and during delayed hypersensitivity reactions (12) . Given that VEGFR2 plays such an important role in many aspects of blood vessel growth, it would be advantageous to monitor VEGFR2 gene expression noninvasively in real time in vivo in various conditions involving angiogenesis.
Recently an in vivo imaging system has been described (19) that allows for real-time assessment of gene induction. Promoters controlling various genes of interest are cloned upstream of the luciferase gene, and these DNA constructs are used to create transgenic animals. Activation of the promoter results in the production of luciferase, which can be non-invasively monitored using a highly light sensitive IVIS ® imaging system. The close relationship between VEGFR2 expression and endothelial cell proliferation makes the VEGFR2 gene an ideal candidate to apply this imaging technology to study angiogenesis. For this purpose, we have established a Vegfr2-luc transgenic mouse model using the murine VEGFR2 promoter to direct the expression of a luciferase reporter.
We have applied this model to study VEGFR2 expression during wound healing and contact hypersensitivity (CHS). Our results confirm that VEGFR2 expression is induced during both
processes. We further demonstrate that the glucocorticoid dexamethasone inhibits VEGFR2 expression during wound healing and CHS, and this change in VEGFR2 expression correlates with (22) . LL/2, and T241 cells were cultured in Dulbecco's Modified Eagle's Medium (Gibco/Invitrogen, Carlsbad, CA) supplemented with 10% heat inactivated fetal calf serum (FCS, Gibco/Invitrogen) plus antibiotics (100 U/ml penicillin-G and 100 U/ml streptomycin). HepG2 and Hela cells were cultured in Minimum Essential Medium (Gibco/Invitrogen) supplemented with 10% heat inactivated fetal calf serum and antibiotics (100 U/ml penicillin-G and 100 U/ml streptomycin). The cells were cultured at 37 o C in a humidified incubator under a 5% CO2 (BAEC, MLTC-1, HepG2, Hela and T241) or 10% CO2 (LL/2) atmosphere.
Transient transfection and luciferase assay
Cells were plated into 24-well plates and transiently transfected with Lipofectamin (Invitrogen, Carlsbad, CA) using pVegfr2-luc plasmid DNA with pRL-TK renilla luciferase vector (Promega, Madison, WI) as an internal control for transfection efficiency. Thirty -six hours following transfection, cells were lysed and assayed for luciferase activity using the Dual Luciferase ® Reporter System (Promega) and a Turner Design TD 20/20 Luminometer (Sunnyvale, CA).
Luciferase signal from the pVegfr2-luc construct was normalized to the renilla luciferase signal to control for the variation of transfection efficiency.
In vitro regulation of VEGFR2 expression
Sixteen hours after transfection, BAEC cells were plated into 24-well plates to 60-70% confluency.
Cells were treated for 36 hours with either mithramycin (0.1 and 1 µM), or fumagillin (1 and 10 µM), or 2-methoxyestradiol (1 and 10 µM). All these compounds were purchased from SigmaAldrich. After treatment, cells were lysed and analyzed for luciferase activity as above. To study
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the effect of cell proliferation on VEGFR2 expression, transiently transfected cells were plated into 24-well plates with cell numbers between 50,000 (50K) and 400,000 (400 K). Cell density was between 10% and 80% confluency. Cells were incubated for 60 hours and assayed for luciferase activity. At the time of harvesting, cells were at about 40-60% (50 K), 60-90% (100 K), 90-100%
(200 K) and 100% (400 K) confluencies.
In vivo imaging of luciferase activity
In vivo imaging was performed as previously described (19) using an IVIS ® imaging system (Xenogen Corp.). Vegfr2-luc transgenic mice were anesthetized with isoflurane and injected intraperitoneally with 150 mg/kg of luciferin (Biosynth, A.G., Switzerland). Ten minutes after luciferin injection mice were imaged for 1-5 minutes. Photons emitted from specific regions were quantified using LivingImage ® software (Xenogen Corp.). In vivo luciferase activity is presented in photons /second.
Tissue luciferase activity
Mouse tissues were removed and homogenized in 3 volumes of PBS containing a protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and lysed with passive lysis buffer (Promega).
After centrifugation at 14,000-rpm for 10min at 4 0 C, the supernatant was collected. Luciferase activity was measured by luminometer using a Luciferase Assay System (Promega). Protein concentration was estimated by Bradford reagent (Sigma-Aldrich).
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From Bioluminescence in Vegfr2-luc mice during development Dorsal and ventral bioluminescent images were collected from Vegfr2-luc mice at 2, 3, 4, 6, 8, 10 and 15 weeks of age (n=3 per time point). The total bioluminescent signal in photons/second was normalized to surface area (cm 2 ) in order to correct for size differences between ages. At each time point, mice were euthanized by an overdose of anesthesia and tissues were rapidly removed and processed to determine luciferase content by luminometer.
Cutaneous wounding procedure
Female Vegfr2-luc mice of 10-15 weeks of age were used. A punch wound was created on the back of each mouse as described (23) . Briefly, the hair on the back of the mice was shaved. analyses, the wound area including the scab and the complete epithelial margin was excised. As a control, a similar amount of skin was taken from the backs of non-wounded mice.
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Induction of contact hypersensitivity (CHS) reactions
Oxazolone (Sigma-Aldrich) was used to induce CHS reactions as described in the literature (13) .
Briefly, female Vegfr2-luc mice at 10-15 weeks of age were sensitized by topical application of 50 µl of 2% oxazolone solution (in acetone/olive oil, 4:1 vol/vol) to the shaved abdomen. Six days after sensitization, the right ear was challenged by topical application of 10 µl of a 1% oxazolone solution, and the left ear was treated with vehicle (acetone/olive oil, 4:1) alone. The extent of inflammation was assessed daily by measuring ear thickness with a micrometer (46) . Bioluminescent images were collected on the day of sensitization, and daily for 5 days following oxazolone challenge. To study the effect of DEX on CHS, mice were i.p. injected with DEX (10 mg/kg) daily beginning one day prior to the oxazolone challenge. Control mice were i.p. injected with saline. Right ear biopsy specimens from 4 mice of each group were obtained 2 days after oxazolone challenge for histology.
Histology and immunohistochemistry
Isolated tissues were immersion-fixed in 4% paraformaldehyde (pH 7.4) for 4 hours and rinsed in 70% ethanol overnight. The samples were embedded in paraffin, and sections were taken for hematoxylin and eosin (H&E) and giemsa staining. Capillaries were immunostained with a monoclonal rat antibody against CD31 (BD Pharmingen, San Diego, CA). Briefly, 4-micron paraffin sections were deparaffinized and placed in PBS. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide. Sections were blocked with the blocking solution provided in the Vectastain Elite ABC Rabbit IgG Kit (Vector Laboratories, Burlingame, CA) to reduce nonspecific staining. The sections were incubated overnight at 4°C with the anti-CD31 antibody, followed by incubation with a biotinylated rabbit anti-rat (mouse absorbed) polyclonal antibody Severity of inflammatory cell infiltration into the epidermis and dermis were scored separately on a scale of 0-5 as follows. 0=Normal, 1=Minimal infiltration, 2=Mild infiltration, 3=Moderate
infiltration, 4=Marked infiltration, 5=Severe infiltration.
Northern blot analysis of VEGFR2 expression
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Tissues were collected from three female Vegfr2-luc mice (8 weeks of age), pooled and frozen in liquid nitrogen. Total RNA was isolated using RNAqueous ® kit (Ambion, Austin, TX). A total of 4 µg of RNA was analyzed by northern blot using the NorthernMax ® system (Ambion). A 1.6-kb VEGFR2 cDNA fragment was amplified (forward primer, CTGTGGTGATCCCCTGCCGAG; reverse primer, CGTTCACAGCGCTCATCCAAGG) using a mouse 17-day embryo cDNA library (Clontech, Palo Alto, CA) and cloned into the pBlueScript SK vector that was linearized with BamH1 and SacI. The VEGFR2 cDNA vector was then linearized with PmlI. Single strand antisense RNA probe was prepared by transcription with T7 polymerase using Strip-EZ™ (Ambion).
After hybridization, the signals were detected using a Bright-Star ® BioDetect TM kit (Ambion).
Results

In vitro regulation of VEGFR2 expression
The Vegfr2-luc transgene vector was constructed as described in the materials and methods. It contains a 4.5-kb murine VEGFR2 promoter fragment upstream of the luciferase gene and a 0.5-kb fragment from the first VEGFR2 intron placed downstream of the luciferase gene in the vector.
This intron fragment was shown to enhance VEGFR2 expression in endothelial cells (21) . Since VEGFR2 expression is induced during angiogenesis, we studied the effect of cell proliferation on VEGFR2 expression. As shown in Figure 1C , we observed a reverse correlation between cell density and Vegfr2-luc expression in transfected BAEC cells, but not in Hela cells, indicating that VEGFR2 expression in endothelial cells is highly dependent on cell proliferation.
Expression of the
Vegfr2-luc expression during post-natal development
Several founder transgenic mouse lines were established, and all of them showed high levels of luciferase expression in 1-2 week old mice, which dropped dramatically with age. We chose one Page #16
expressed per cm 2 of animal surface area to correct for differences in animal size at different ages.
Data are presented as mean ± standard error (n=3).
Adult Vegfr2-luc mice were sacrificed and tissue samples were collected and processed to determine luciferase activity ex vivo ( Figure 3A) . In female mice, luciferase activity was highest in lung and uterus, intermediate in heart, skin, kidney, and lower in liver, spleen, intestine and skeletal muscle. Northern blot analysis with a VEGFR2 probe detected the 5.9-kb VEGFR2 mRNA in all the tissues. Gene expression, by RNA analyses, was highest in lung, uterus and heart, intermediate in skin and kidney, and lower in the other tissues ( Figure 3B ). These data suggest that luciferase expression in most of the tissues correlates with endogenous VEGFR2 expression. Male Vegfr2-luc mice had a similar pattern of luciferase and endogenous VEGFR2 mRNA expression in all the tissues except the testis, which showed a high level of luciferase expression and a low-level of VEGFR2 mRNA expression (data not shown). 
Vegfr2-luc expression is induced during wound healing and is inhibited by dexamethasone
Punch wounds were generated on the backs of female Vegfr2-luc mice, and luciferase expression in the wound area was monitored for three weeks. As shown in Figure 4A , luciferase expression was detectable one day after wounding and reached a peak between 7 and 10 days post wounding.
Luciferase expression decreased in the later stages of wound repair but was still detected at day 21 when reepithelialization was complete ( Figure 4A ). Quantification of the signal showed that luciferase expression in the wounded area was induced more than 6 fold at the peak ( Figure 4B ).
Figure IV.
For The effect of glucocorticoids on VEGFR2 expression during wound healing was investigated using another set of female Vegfr2-luc transgenic mice. Punch wounds 8 mm in diameter were generated on the backs of the mice. The mice were i.p. injected with dexamethasone (DEX) or saline daily, starting one day prior to wounding. Administration of dexamethasone significantly inhibited luciferase expression as compared to control mice treated with saline ( Figure 5A ). Quantification showed luciferase signal in DEX treated mice was induced 2-3 fold at the peak, which is significantly less than the luciferase induction in saline treated mice ( Figure 5B ). The inhibition of Vegfr2-luc expression by dexamethasone was correlated with delayed wound closure. Wound closure was monitored by measurement of wound area and the comparison of the two groups is shown in Figure 5C . Dexamethasone-treated mice took 9 days for the wound to close to 50% of the original size, whereas the control mice took 5.5 days to reach 50% closure.
For 
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software. Data is shown as mean ± standard error. C. Wound area was measured and shown as percentage of the initial wound area on Day 0. Data presented are mean ± standard error.
Histological analysis of the effect of dexamethasone on wound healing
We examined whether the observed inhibitory effect of dexamethasone on Vegfr2-luc expression and wound healing correlate with histological changes in the tissue. The distribution of capillaries and blood vessels in the wound tissue specimens was determined by staining with a rabbit polyclonal antibody against CD31, an endothelial junction molecule (5) . As compared with control non-wounded skin tissue, wound tissues from saline-treated mice showed a marked increase of capillary density and blood vessel number in the granulated tissues. The blood vessels were of relatively small caliber without prominent branching. In DEX treated wounds, the blood vessels in the granulated tissue were of larger caliber ( Figure 6A ). Leukocyte infiltration in the wound tissues was examined with an anti-CD11b antibody (13) . Compared to control non-wounded skin tissues, saline-treated wounds had significant infiltration of leukocytes, primarily macrophages, into the tissue. Dexamethasone-treated wounds had markedly less macrophage infiltration ( Figure 6B ).
Expression of VEGFR2 in wound tissues was examined using a VEGFR2 antibody ( Figure 6C,D) . 
Vegfr2-luc expression was induced during contact hypersensitivity (CHS) reactions and was inhibited by dexamethasone
Vegfr2-luc female mice were sensitized with oxazolone, 
B. Giemsa staining, (400x magnification). Normal control skin has dermal mast cells (brown
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Figure IX.
Discussion
Angiogenesis is a hallmark of wound healing (12, 17) and a variety of inflammatory diseases, including contact hypersensitivity (13) . There is considerable evidence to suggest that angiogenesis and inflammation are closely linked (24) . Blood vessels at the site of inflammation are enlarged and hyper-permeable in order to maintain blood flow to meet the increased metabolic demand of the tissue (24) . VEGFR2 is a receptor, expressed in endothelial cells and other cell types, that mediates mitogenic signaling during angiogenesis. Expression of VEGFR2 is up regulated during wound healing (17) and hypersensitive skin reaction (13) . Therefore, the transcriptional regulation of the VEGFR2 gene may be an important factor in wound healing and in some inflammatory diseases. We have developed a transgenic mouse model that uses the promoter from the murine VEGFR2 gene to drive luciferase expression and we have used it to study the transcriptional regulation of VEGFR2 in vivo using optical imaging.
The VEGFR2 promoter contains many regulatory sequences such as Sp1, NF-B binding sites and a palindromicGATA site (25, 26, 48) . These regulatory sequences have been shown to mediate in vitro VEGFR2 induction by TNF-alpha (27) , VEGF and nitric oxide (28) and suppression by TGFbeta (48) . In addition, endothelial cell specific regulatory elements have been identified within the VEGFR2 promoter sequence (20) and the intron fragment (21) . We confirmed that the Vegfr2-luc transgene cassette is able to mediate higher luciferase expression in a BAEC endothelial cell line compared with several non-endothelial cell lines. We further showed that Vegfr2-luc expression was suppressed by angiogenesis inhibitors mithramycin, fumagillin and 2-methoxyestradiol. In addition, we demonstrated that Vegfr2-luc expression was positively correlated with endothelial cell proliferation. These data suggest that VEGFR2 expression can be regulated in vitro and lead to The kinetics of VEGFR2 expression during cutaneous wound healing has not been previously reported. In our wound-healing experiment with the Vegfr2-luc mice, we demonstrated that luciferase expression was induced at the earliest stages of wound healing with a peak induction observed between 7 and 10 days post-wounding. The luciferase expression was still detectable at day 21 when reepithelialization was complete. These findings suggest that VEGFR2 expression is increased during the endothelial cell mitogenesis phase, and is maintained during the vascular remodeling phase. A recent study also confirmed that VEGFR2 is expressed during the later stages of wound healing (31) . Taken together, these results suggest that VEGFR2 expression may be critical to both endothelial cell proliferation as well as the sprouting, branching and differential growth of blood vessels during tissue remodeling. Immunohistochemical analysis of the wound tissues collected 7 days post-wounding showed increased vascular density compared to normal non-wounded skin tissues. The blood vessels were of small caliber and straight without prominent branching, suggesting that at 7 days post wounding the skin tissue was still in the mitogenesis phase and significant sprouting had not yet occurred. Significant macrophage infiltration was observed in the wound tissue. We confirmed VEGFR2 expression in endothelial cells by immunostaining with VEGFR2 antibody. In addition, stromal cells in the granulated tissue were also stained by the VEGFR2 antibody.
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The Vegfr2-luc reporter was also clearly induced in the ear in a model of contact hypersensitivity.
Contact hypersensitivity is a two-phase process. The induction phase begins upon initial epicutaneous application of a hapten (low molecular weight chemical), resulting in activation and rapid lymphocyte proliferation (32) . The challenge or elicitation phase occurs when sensitized individuals are re-exposed to the sensitizing antigen. This local CHS reaction is characterized by infiltration of T lymphocytes, macrophages and neutrophils (33) . Since angiogenesis is an important part of the CHS reaction (33), we predicted that the Vegfr2-luc mouse could be used to study the angiogenic component of the CHS response. We showed an induction of luciferase expression in mouse ears with a peak response 2 days after oxazolone challenge. We confirmed that luciferase activity correlated with increased VEGFR2 expression in the ear tissue by immunostaining with a VEGFR2 antibody. Histological analysis showed pronounced inflammatory infiltrate in the ear tissue. Since the peak of luciferase occurs later than the peak of ear swelling, it is possible that VEGFR2 expression and the angiogenesis activity is a result of the early inflammatory response in the CHS test.
The increased intensity of VEGFR2 staining in the wound tissues ( Figure 6C ,D) and oxazolone challenged ear tissues ( Figure 8C ) was less than the increased gene induction, as luciferase expression was induced by up to 6-fold in the wound tissue ( Figure 4 ) and by up to 28-fold in oxazolone challenged ear tissues ( Figure 7) . This difference could be due to two factors. First, the induction of luciferase signal in the wound tissues was the combined effect of the luciferase expression increase in endothelial and stromal cells and the increased cell number after wounding.
Our immunohistochemical data clearly demonstrated the increase of both blood vessel numbers ( Figure 6A ) and VEGFR2 expressing stromal cells ( Figure 6C ) in the granulated wound tissues. Previous studies have also demonstrated that VEGFR2 is expressed in non-endothelial cells, such as skeletal myocytes (5), chondrocytes and osteoclasts (34) , smooth muscle cells of the uterus (35) and intratumoral stromal cells (36) . Consistent with these studies, we observed VEGFR2 expression in the stromal cells of the wound tissues and several other types of cells in the ear after oxazolone challenge. Expression of VEGFR2 in non-endothelial cells suggests VEGFR2 may have other functions in addition to mediating endothelial cell proliferation and blood vessel growth.
In the cutaneous wounding model, dexamethasone delayed healing. It also reduced ear swelling in the CHS test, consistent with previous reports in the literature (37) . In both wound healing and CHS, dexamethasone significantly decreased induction of the Vegfr2-luc reporter and this was associated with an inhibition of inflammatory cell infiltration. Inhibition of macrophage infiltration Page #34
could be the critical factor that slows angiogenesis and delays wound healing. Macrophages play an important role in the regulation of angiogenesis in both normal and diseased or damaged tissues (38) . Macrophage infiltration into the wound peaks between day 2 and day 4. By day 2, macrophages are the predominant leukocyte in the wound space and persist through the remodeling phase (30) . After activation by wound microenvironmental stress factors, such as hypoxia and lactate, macrophages secrete an array of angiogenic cytokines, growth factors and proteolytic enzymes, which are central to their proangiogenic activity and the formation of neovessels (39, 40) .
In addition, in wound tissue (41) and tissue with CHS reaction (42) , activated macrophages express the inducible form of nitric oxide synthase (iNOS), which is the major source of nitric oxide (NO) production in these tissues. Since the peak of VEGFR2 expression after wounding occurs after the peak of macrophage infiltration, it is likely that macrophages play a direct role in inducing VEGFR2 expression by secreting cytokines, growth factors and nitric oxide.
Regulation of VEGFR2 expression seems to have a profound effect on angiogenesis. Previous studies showed that VEGFR2 expression in vitro can be induced TNF-alpha (27) , NO and VEGF (28) and suppressed by TGF-beta (48, 49) . These angiogenic/anti-angiogenic molecules, by modulating the expression of genes such as VEGFR2, regulate endothelial cell proliferation and angiogenesis under pathophysiological conditions such as wound healing (17, 50) .
Dexamethasone has been well characterized for its ability to inhibit inflammatory cytokine production (43) and iNOS synthesis (44) by macrophages. Dexamethasone may decrease VEGFR2 expression and endothelial cell proliferation through inhibiting macrophage infiltration and production of cytokines, growth factors and nitric oxide by macrophages, and interfere with the 
